For active‐Caspase 3, compared with the control group, there was no difference between the sorafenib and CU27 groups, while the combination therapy group significantly increased active‐Caspase 3+ cells, indicating a significant synergistic effect of CU27 and sorafenib in HCC cell apoptosis. This evidence concerns the gene CASP3 and hepatocellular carcinoma.